The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC

Name: No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC
Uploaded: 2019-09-28T00:00:00Z
Duration: 58 s
Description: Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase I study evaluating rovalpituzumab tesirine (ROVA-T) in the frontline treatment of patients with extensive-stage small-cell lung cancer (NCT02819999). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Ross Camidge • 28 Sep 2019

ESMO 2019

General Lung Cancer Small Cell Lung Cancer Antibodies Rovalpituzumab tesirine

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase I study evaluating rovalpituzumab tesirine (ROVA-T) in the frontline treatment of patients with extensive-stage small-cell lung cancer (NCT02819999). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.